Eurofins Medical Device Services Launches first GMP PFAS Screening and Testing Solutions for Medical Devices
News > Business News
Audio By Carbonatix
6:00 AM on Tuesday, December 2
The Associated Press
LANCASTER, Pa.--(BUSINESS WIRE)--Dec 2, 2025--
Eurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launched a GMP PFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributing to medical device and patient safety.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202959694/en/
Eurofins Medical Device Services is setting new standards with the industry's first GMP PFAS testing and advanced PFAS Risk Assessments for medical devices.
Per- and polyfluoroalkyl substances, or PFAS, are a group of more than twenty thousand chemical compounds which are highly resistant to degradation and have been found to pose potential threats to human health and the environment. Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates and avoid future shutdowns, recalls, and liability issues, while further supporting their sustainability goals.
Eurofins Medical Device Services North America’s GMP PFAS testing and screening solution includes:
- Combustion Ion Chromatography (CIC) for total organic fluorine screening in solids, liquids, and gases, to provide an initial assessment of PFAS levels.
- Process mapping and supply chain audits, to identify contamination pathways.
- Solvent extraction and direct combustion for flexible sample formats.
- Extractables & Leachables (E&L) testing, toxicological risk assessments, and aging studies.
- Stability and forced degradation studies, to identify PFAS breakdown products.
Eurofins Medical Device Services North America operates under ISO 17025 accreditation standards, and applies GMP best practices, ensuring sensitivity, specificity, and reproducibility even at trace levels.
Learn more at https://www.eurofins.com/medical-device/
About Eurofins Medical Device Services
Eurofins Medical Device Services offers comprehensive testing, consulting, and regulatory support for Class I, II, and III medical devices—including implants, instruments, single-use and combination products, and wearables.
With more than 40 years of experience, our global network of medical device testing laboratories and consultants provide strategic guidance from biological evaluation plans through commercialization, and specialize in international regulatory requirements, scientific trends, and tailored testing strategies.
Committed to global standards, Eurofins Medical Device Services designs and executes testing plans aligned with ISO, ASTM, ANSI, and AAMI standards, as well as custom methodologies. Our quality systems meet GMP and ISO 17025 requirements, helping clients accelerate market access with confidence.
View source version on businesswire.com:https://www.businesswire.com/news/home/20251202959694/en/
CONTACT: For further information:
Lisa Bamford
Medical Device Services Communications Director
KEYWORD: PENNSYLVANIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: PUBLIC POLICY/GOVERNMENT BIOTECHNOLOGY OTHER MANUFACTURING HEALTH MEDICAL DEVICES CHEMICALS/PLASTICS PUBLIC SAFETY MANUFACTURING
SOURCE: Eurofins
Copyright Business Wire 2025.
PUB: 12/02/2025 09:00 AM/DISC: 12/02/2025 09:00 AM
http://www.businesswire.com/news/home/20251202959694/en
